Over time, the body's own tissue grows over the implanted Watchman device, fully incorporating it into the heart's structure. This process, known as endothelialization, promotes long-term stability and reduces the risk of device-related complications. The Watchman device is designed to be permanent...
Introduction:Watchman device implant reduces various cardio-cerebral events in patients with left atrial appendage. As there is a lack of data on device failure among the elderly undergoing this procedure, we aim to provide a perspective via the 2016-2020 National Inpatient Sample(NIS).#Methods:...
stroke, TIA, intracranial hemorrhage, systemic embolism, major bleeding, major vascular complications, MI, pericardial effusion requiring intervention, and device embolization. A significant difference favoring the Watchman FLX was seen overall and for the following events: ...
This was a retrospective cohort study assessing the duration of antiplatelet and anticoagulant therapy in 47 consecutive patients following WATCHMAN implant. The primary outcome was rate of major bleeding, stroke and systemic embolic complications. The secondary endpoints were rate of device thrombus and ...
The device met all three primary endpoints in the first head-to-head comparison, but eyebrows were raised over procedural complications and high bleeding rates.
SURGICAL complicationsIntroduction: Incomplete anchoring of the Watchman left atrial appendage closure (LAAO) device can result in substantial device migration or device embolization (DME) requiring percutaneous or surgical retrieval. Methods: We performed a retrospective analysis of Watchman procedures (...
Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri- procedural outcomes from the EWOLUTION registry. Eur Heart J. Epub 2016 Jan 27.Boersma LV, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN ...
Our registry in a high-risk population treated with the innovative Watchman FLX device, showed high technical procedural success with easy implant and repositioning, no embolization, good LAA sealing and low rate of ischaemic/bleeding complications. 637 Figure...
The PROTECT AF trial revealed that LAA closure using the Watchman device was non-inferior to Warfarin for preventing stroke in AF pts with CHADS2 ≥ 1. However, these pts were treated with Warfarin post-implant until a TEE demonstrated LAA...